Supernus Pharmaceuticals, Inc.

Fundamentals6.0
Price Action6.0
News Sentiment0.0
AI Rating
6.0

Key Drivers

  • Gross Margin
  • Expense Pressure
  • Cash Strength

AI
AI Summary

6.0

SUPN has shifted from a survival story to an execution story, with strong revenue growth, ~90% gross margins and ample cash giving it room to build operating leverage, but the stock already prices in improvement so investors should watch whether it can sustain growth, keep margins rising, and break/hold above $48 without slipping back on valuation concerns.

GrowthOpportunity
ValuationRisk
Momentum‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Gross Margin
  • Expense Pressure
  • Cash Strength

SUPN has strong gross margins and a solid cash-rich balance sheet, but persistent operating losses, weak asset efficiency, and a valuation that still depends on future profitability.

profitability
liquidity

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Higher lows
  • Near resistance
  • Trend intact

SUPN remains constructive in the short term, with higher lows and about a 9% gain, but it is now pressing near $48 resistance so upside likely depends on a clean breakout while $46.5 support holds.

uptrend
resistance
Support Level: $46.5-$46.8, then $44.4-$44.8
Resistance Level: $48.0

Late-June bounce lifted shares from the low-$44s to $48.05 and near the top of the recent range

Sentiment & News

0.0